Search Results - "Vano, Y. A."

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series by Rodrigues, M.J., Peron, J., Frénel, J.-S., Vano, Y.-A., Wassermann, J., Debled, M., Picaud, F., Albiges, L., Vincent-Salomon, A., Cottu, P.H.

“…Randomized clinical trials showed the benefit of adjuvant trastuzumab-based chemotherapy (ATBC) for node-positive and/or >1 cm HER2+ breast carcinomas. No…”
Get full text

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs) by Daban, A, Gonnin, C, Phan, L, Saldmann, A, Granier, C, Lillo-Lelouet, A, Le Beller, C, Pouchot, J, Weiss, l, Tartour, E, Fabre, E, Medioni, J, Oudard, S, Vano, YA, Dragon-Durey, MA, Simonaggio, A.

“…Introduction: Immune checkpoint inhibitors (ICIs) are now standard of care in many cancers. They can generate immune-related adverse events (irAEs), but no…”
Get full text

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study by Barthélémy, P., Albigès, L., Escudier, B., Narciso, B., Bigot, P., Chehimi, M., Emambux, S., Calcagno, F., Mouillet, G., Eymard, J.-C., Schlürmann, F., Bailly, S., Garbay, D., Berdah, J.-F., Palmaro, M.B., Goupil, M.G., Spaeth, D., Néré, S., Quentric, C., Vano, Y.-A., Thiery-Vuillemin, A.

“…Nivolumab is the first immune checkpoint inhibitor approved in Europe for the treatment of advanced renal cell carcinoma (aRCC) in patients resistant to prior…”
Get full text

Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab by Simonaggio, A., Elaidi, R., Fournier, L., Fabre, E., Ferrari, V., Borchiellini, D., Thouvenin, J., Barthelemy, P., Thibault, C., Tartour, E., Oudard, S., Vano, Y. A.

“…Background An elevated pre-treatment neutrophil to lymphocytes ratio (NLR) is associated with poor prognosis in various malignancies. Optimal cut-off is highly…”
Get full text

Quelle stratégie thérapeutique pour les stades métastatiques ? by Simonaggio, A., Rivallin, G., Marret, S., Oudard, S., Vano, Y.-A.

“…La prise en charge thérapeutique des carcinomes rénaux métastatiques à cellules claires a progressé de manière majeure sur la dernière décennie avec…”
Get full text

Lien épidémiologique entre comportement alimentaire et cancer: exemple du cancer colorectal by VANO, Y.-A, RODRIGUES, M.-J, SCHNEIDER, S.-M

Get full text

Elderly patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with Nivolumab (N): A subgroup analysis from the WITNESS real-world study in France by Barthélémy, P., Thiery-Vuillemin, A., Escudier, B., Eymard, J-C., Mouillet, G., Schlürmann, F., Chartier, M., Quentric, C., Vano, Y-A., Albiges, L.

Get full text

IO-Synthesise RCC: A pooled analysis of real-world outcomes for advanced renal cell carcinoma patients treated with nivolumab in France and Germany by Thiery-Vuillemin, A., Bedke, J., Albigès, L., Bigot, P., Escudier, B., von der Heyde, E., Grünwald, V., Müller-Huesmann, H., Narciso, B., Schostak, M., Schultze-Seemann, W., Vano, Y-A., Allan, V., Chartier, M., Herber, M., McDonald, L., Quentric, C., Barthélémy, P., Grimm, M-O.

Get full text

Epidemiological link between eating habits and cancer: the example of colorectal cancer by Vano, Y-A, Rodrigues, M-J, Schneider, S-M

“…One million people worldwide are affected by colorectal cancer (CRC) every year, resulting in 500,000 deaths. Incidence rate varies widely according to areas…”
Get more information

A phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer: the BIONIKK trial by Elaidi, R.T., Oudard, S., Braychenko, E., Sun, C-M., Sautès-Fridman, C., Vano, Y-A.

Get full text

1461P Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era by Thouvenin, J., Alhalabi, O., Carlo, M., Carril Ajuria, L., Bakouny, Z., Martinez Chanza, N., Negrier, S., Campedel, L., Bilen, M.A., Borchiellini, D., Chahoud, J., Vano, Y-A., Lodi, M., Barthelemy, P., Viswanathan, S.R., Msaouel, P., Choueiri, T.K., Albiges, L., Tannir, N., Malouf, G.

Get full text

1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial by Meylan, M., Sun, C-M., Elaidi, R-T., Moreira, M., Bougouin, A., Verkarre, V., Bennamoun, M., Chevreau, C.M., Borchiellini, D., Barthelemy, P., Pannier, D., Maillet, D., Gross Goupil, M., Tournigand, C., Braychenko, E., Phan, L., Oudard, S., Fridman, W-H., Sautes-Fridman, C., Vano, Y-A.

Get full text

1460P IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany by Mouillet, G., Bedke, J., Albiges, L., Barthelemy, P., Escudier, B., Gruenwald, V., Ivanyi, P., Mueller-Huesmann, H., Vano, Y-A., von der Heyde, E., Ejzykowicz, F., Brellier, F., Herber, M., Quentric, C., Bennett, B.M., Nere, S., Autengruber, A., Thiery-Vuillemin, A., Grimm, M-O.

Get full text

1468P IO-synthesise RCC: Real-world outcomes of nivolumab in patients (pts) with previously treated advanced non-clear cell renal cell carcinoma (nccRCC) – A pooled analysis from France and Germany by Barthelemy, P., Bedke, J., Albiges, L., Grünwald, V., Escudier, B., Mueller-Huesmann, H., Vano, Y-A., Ivanyi, P., Bigot, P., von der Heyde, E., Narciso, B., Belz, H., Nere, S., Quentric, C., Brellier, F., Herber, M., Thiery-Vuillemin, A., Grimm, M-O.

Get full text

Alimentation et cancer: quelles évidences, quelles recommandations ? by Vano, Y. -A., Schneider, S. -M.

“…Résumé On estime qu’un tiers de la mortalité par cancer est dû à l’alimentation ou au statut nutritionnel. Légumes et/ou fruits diminuent les risques de cancer…”
Get full text

P181 WITNESS: Real-world outcomes of Nivolumab (NIVO) + Ipilimumab (IPI) in patients (pts) with previously untreated clear cell advanced Renal Cell Carcinoma (aRCC) in France - 1 year minimum follow-up by Barthélémy, P., Vano, Y-A., Eymard, J-C., Narciso, B., Martin, S., Bigot, P., Chehimi, M., Bennamoun, M., Mouillet, G., Moreira, A., Solub, D., L Haridon, T., Gimel, P., Mahammedi, H., Thiery-Vuillemin, A., Petit, G., Escudier, B., Albigès, L.

Get full text

Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases by Elaidi, R., Vano, Y.A., Aide, N., Fournier, L., Deandreis, D., Tenenbaum, F., Lebtahi, R., De Clermont-Galleran, H., Albiges, L., Escudier, B., Joly, F., Alexandre, J., Bernardini, M., Baron, S., Arfi-Rouche, J., Noel, C., Braychenko, E., O'Quigley, J., Medioni, J., Oudard, S.

Get full text

Thérapies ciblées et biomarqueurs compagnons dans les cancers de la prostate métastatiques by Auclin, E., Vano, Y.-A.

“…Le traitement du cancer de la prostate résistant à la castration a connu une révolution ces trois dernières années avec l’autorisation de mise sur le marché de…”
Get full text

Alimentation et cancer : quelles évidences, quelles recommandations ? : Nutrition et cancer by VANO, Y.-A, SCHNEIDER, S.-M

Get full text